Mundipharma Launches Pegfilgrastim Biosimilar in Europe

Goodwin
Contact

On February 5, 2019, Mundipharma announced the European launch of Pelmeg® (pegfilgrastim), a biosimilar of Neulasta®.  As we have previously reported, Mundipharma acquired Pelmeg® from Cinfa Biotech and it was approved by the European Commission in November 2018.  According to the press release, Pelmeg® is now available in Germany, the Netherlands, and Ireland, and the fourth biosimilar medicine to be commercialized by Mundipharma.

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide